Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment Disclosures (Tables)

Segment Disclosures (Tables)

6 Months Ended

Jun. 30, 2014

Schedule of Segment Reporting Information

Segment reporting information is as follows:

	Engineering			Medical
	Services			Devices		Total
Three months ended June 30, 2014
Revenue	$	506,513		$	690,540	$	1,197,053
Cost of revenue		650,043			501,425		1,151,468
Gross profit (loss)	$	(143,530	)	$	189,115	$	45,585

Three months ended June 30, 2013
Revenue	$	594,598		$	389,394	$	983,992
Cost of revenue		384,119			296,869		680,988
Gross profit	$	210,479		$	92,525	$	303,004

Six months ended June 30, 2014
Revenue	$	1,041,471		$	1,217,293	$	2,258,764
Cost of revenue		902,146			831,550		1,733,696
Gross profit	$	139,325		$	385,743	$	525,068

Six months ended June 30, 2013
Revenue	$	957,928		$	722,313	$	1,680,241
Cost of revenue		731,333			529,432		1,260,765
Gross profit	$	226,595		$	192,881	$	419,476

Schedule of Geographic Information

Geographic information for revenue based on location of customer is as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013

North America	$	941,358	$	871,203	$	1,831,143	$	1,494,688

Europe, Middle East Asia		255,695		112,789		427,621		185,553
	$	1,197,053	$	983,992	$	2,258,764	$	1,680,241

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details